Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Im

2022년 1월 3일

GNPX: Genprex, Inc.
2022-01-03 08:00:00
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer